Expanding Access to Women’s Health: Slinda, Ryeqo, and Pergoveris on the PBS in Australia
In a significant step forward for women’s health, the Australian government has announced new and amended listings on the Pharmaceutical Benefits Scheme (PBS), making contraception, endometriosis treatment, and IVF care more accessible and affordable. These changes will benefit thousands of women across the country, reducing financial barriers to essential healthcare.
Slinda: A New Contraceptive Option
From May 1, 2025, Slinda (drospirenone) will be listed on the PBS for the first time. This progestogen-only pill is particularly beneficial for women who cannot take contraceptives containing estrogen, including those at risk of blood clots, migraine sufferers, breastfeeding mothers, and individuals with high blood pressure. Previously, women had to pay over $250 per year for this medication, but the PBS listing will significantly reduce costs.
Ryeqo: A Breakthrough for Endometriosis Treatment
Endometriosis affects thousands of Australian women, often leading to severe pain and complications. Ryeqo (relugolix with estradiol and norethisterone) will also be added to the PBS on May 1, 2025, providing a new treatment option for those who have not found relief with other hormonal therapies or painkillers. Before this listing, patients faced costs exceeding $2,700 per year, but now, the price will drop to between $92 and $380, making it far more accessible.
Pergoveris: Improved Access to IVF Treatment
For women undergoing IVF, the amended listing of Pergoveris (follitropin alfa with lutropin alfa) will take effect from April 1, 2025. This change allows earlier access to combination therapy in the IVF cycle and doubles the number of pens available per script from two to four, easing the financial burden on families seeking fertility treatment.
A Step Forward for Women’s Health
These PBS listings mark a major milestone in improving healthcare access for Australian women. By reducing costs and expanding treatment options, the government is addressing long-standing barriers to contraception, endometriosis management, and fertility care. Health professionals and advocates have welcomed these changes, emphasizing their positive impact on women’s health and well-being.
With these advancements, more women will have the opportunity to make informed choices about their reproductive health without financial strain. As awareness grows, these listings will undoubtedly contribute to better healthcare outcomes for women across Australia.
What do you think about these changes? Do they address the challenges women face in accessing reproductive healthcare? Lets discuss!
